Table 2.
Baseline and Follow-Up Characteristics of PAP Usage Groupings.
| Characteristic* | Baseline | 2 Year Follow Up | ||||||
|---|---|---|---|---|---|---|---|---|
| Full User (N=177) |
Partial User (N=44) |
Non User (N=88) |
p† | Full User (N=177) |
Partial User (N=44) |
Non User (N=88) |
p† | |
| Age (years) | 55.2±10.1 | 56.5±9.0 | 55.4±8.9 | 0.7382 | 57.2±10.1 | 58.5±9.1 | 57.4±8.9 | 0.7323 |
| Male | 80.2% | 81.8% | 76.1% | 0.6708 | -- | -- | -- | -- |
| BMI (kg/m2) | 33.2±4.9 | 32.8±5.1 | 30.5±4.8 | 0.0001 | 34.0±5.0 | 32.8±5.3 | 30.8±4.9 | <0.0001 |
| Epworth Sleepiness Score |
12.7±4.9 | 12.4±4.8 | 10.5±4.7 | 0.0022 | 8.1±4.5 | 9.4±5.2 | 9.0±4.6 | 0.1615 |
| Statin Use | 22.0% | 31.8% | 17.0% | 0.1549 | 27.7% | 34.1% | 21.6% | 0.2900 |
| Hypertension | 48.6% | 59.1% | 27.3% | 0.0004 | 47.2% | 54.5% | 31.8% | 0.0183 |
| Diabetes | 6.3% | 4.5% | 3.4% | 0.6761 | 6.9% | 4.5% | 2.3% | 0.2917 |
| Cardiovascular disease |
13.1% | 15.9% | 17.0% | 0.6659 | 13.6% | 15.9% | 17.0% | 0.7501 |
| Obstructive Lung Disease |
15.8% | 6.80% | 25.3% | 0.0228 | 16.5% | 9.1% | 26.7% | 0.0304 |
| Current Smoker | 17.6% | 13.6% | 20.5% | 0.6231 | 14.7% | 18.2% | 21.6% | 0.3663 |
| Diastolic BP | 83.4±10.4 | 82.3±11.3 | 82.3±9.2 | 0.6377 | 80.2±9.5 | 80.1±10.2 | 80.6±9.1 | 0.9375 |
| Systolic BP | 133.2±13.4 | 131.6±13.6 | 130.2±12.5 | 0.2008 | 134.8±13.3 | 130.6±12.5 | 130.8±11.3 | 0.0197 |
| Total Cholesterol | 195.6±45.3 | 193.6±34.4 | 195.8±45.0 | 0.9583 | 203.1±39.1 | 195.8±37.6 | 209.4±42.8 | 0.1715 |
| LDL Cholesterol | 139.8±41.1 | 137.7±32.2 | 143.0±41.9 | 0.7433 | 139.7±36.8 | 131.8±35.8 | 145.9±40.5 | 0.1218 |
| HDL Cholesterol | 40.8±10.9 | 40.6±7.9 | 38.8±10.5 | 0.3414 | 48.5±10.7 | 49.9±12.1 | 50.6±13.6 | 0.3633 |
| Triglycerides | 172.0±86.1 | 175.0±74.3 | 160.3±59.7 | 0.4425 | 170.5±102.5 | 161.6±85.3 | 147.3±77.9 | 0.1682 |
| AHI (events/hr) | 50.8±20.3 | 44.4±19.4 | 33.6±15.3 | <0.0001 | -- | -- | -- | -- |
| ODI (events/hr) | 41.2±20.7 | 35.5±19.9 | 25.2±14.5 | <0.0001 | -- | -- | -- | -- |
| SaO2 Nadir | 75.9±7.8 | 75.1±8.4 | 79.1±7.0 | 0.0021 | -- | -- | -- | -- |
| % Time SaO2 <90% |
15.4±18.6 | 13.8±17.6 | 6.2±11.1 | 0.0001 | -- | -- | -- | -- |
| ICAM-1 (ng/ml) | 299.3±79.8 | 295.4±92.2 | 311.8±110.4 | 0.4982 | 286.9±71.0 | 292.7±84.9 | 315.9±103.0 | 0.0286 |
| VCAM-1 (ng/ml) | 861.1±320.1 | 855.0±268.6 | 962.3±289.9 | 0.0298 | 955. ±371.6 | 987.3±367.6 | 1,069.6±329.2 | 0.0535 |
*
Demographic and clinical characteristics are shown at baseline and at two year follow up within strata defined by PAP usage (full, partial, or non) at follow up. Continuous characteristics are presented as means ± standard deviations (SD) and categorical covariates as percentages;
†
p-value from ANOVA (continuous variables) or chi-square or exact test (categorical variables) testing whether there were differences among PAP usage groups; Significant differences (p<0.05) are shown in bold.
Abbreviations: BMI: body mass index; AHI: apnea hypopnea index; ODI: oxygen desaturation index; SaO2 oxygen saturation; ICAM-1 Intracellular Adhesion Molecule 1; VCAM-1 Vascular Adhesion Molecule 1